½ÃÀ庸°í¼­
»óǰÄÚµå
1535590

Ä­µð´Ù ¿ÜÀ½Áú¿°(VVC) Ä¡·á ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°, Áúȯ À¯Çü, Åõ¿© °æ·Î, À¯Çü, À¯Åë ä³Î, ¼¼°è ¿¹Ãø(2024-2032³â)

Vulvovaginal Candidiasis (VVC) Treatment Market - Drug Class, Disease Type, Route of Administration, Type, Distribution Channel, Global Forecast 2024-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 190 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ Ä­µð´Ù ¿ÜÀ½Áú¿°(VVC) Ä¡·á ½ÃÀåÀº ´ëÇü Á¦¾àȸ»çÀÇ Á¦Ç° Ãâ½Ã ±ÞÁõ¿¡ ÀÇÇØ 2024-2032³â CAGR 4.5%¸¦ ±â·ÏÇÕ´Ï´Ù.

VVC´Â Ä­µð´Ù Á¾¿¡ ÀÇÇØ ¹ß»ýÇÏ´Â ÈçÇÑ Áø±Õ °¨¿°ÁõÀ¸·Î Àü ¼¼°è¿¡¼­ ¼ö¹é¸¸ ¸íÀÇ ¿©¼ºÀÌ ¾Î°í ÀÖÀ¸¸ç, È¿°úÀûÀÎ Ä¡·á¿¡ ´ëÇÑ ¿ä±¸°¡ Ä¿Áö°í ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó ÇコÄÉ¾î ºÐ¾ßÀÇ ÁÖ¿ä ±â¾÷Àº ¿Ü¿ë Å©¸², ¸Ô´Â ¾à, Áú ÁÂ¾à µî ´Ù¾çÇÑ Çõ½ÅÀûÀÎ Ç×Áø±Õ Ä¡·áÁ¦¿Í ÀϹÝÀǾàǰÀ» Ãâ½ÃÇϰí ÀÖ½À´Ï´Ù.

¿¹¸¦ µé¾î 2024³â 2¿ù, ½Å»ý ¹ÙÀÌ¿À Á¦¾à ±â¾÷ Mycovia Pharmaceuticals, Inc.´Â Jiangsu Hengrui Pharmaceuticals Co, Ltd.°¡ Áß±¹¿¡¼­ VIVJOA(R)(¿ÀÅ×¼¼ÄÚ³ªÁ¹)¸¦ Á¤½ÄÀ¸·Î Ãâ½ÃÇß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ Çõ½ÅÀûÀÎ °æ±¸¿ë ¾ÆÁ¹°è Ç×Áø±ÕÁ¦´Â ÀÌÁ¦ ÁßÁõ ¿ÜÀ½ºÎ Ä­µð´ÙÁõ(VVC) Ä¡·á¿¡ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ·¯ÇÑ ½ÅÁ¦Ç° Ãâ½Ã´Â º¸´Ù È¿°úÀûÀ̰í Á¢±Ù¼ºÀÌ ³ôÀ¸¸ç ȯÀÚ Ä£È­ÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇϱâ À§ÇÑ °ÍÀÔ´Ï´Ù. °¢ ȸ»ç´Â È¿´ÉÀ» °³¼±Çϰí, Àç¹ß·üÀ» ³·Ã߸ç, ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­Çϱâ À§ÇØ ¿¬±¸°³¹ß¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. »õ·Î¿î Á¦Çü°ú Àü´Þ ¹æ¹ýÀ» µµÀÔÇÏ´Â °ÍÀº ´Ù¾çÇÑ È¯ÀÚµéÀÇ ¿ä±¸¿¡ ºÎÀÀÇϰí Ä¡·á °á°ú¸¦ °³¼±Çϱâ À§ÇÑ ³ë·ÂÀ» ¹Ý¿µÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀ¸·Î ½ÃÀåÀÌ È®´ëµÊ¿¡ µû¶ó ¿ÜÀ½ºÎ Á¾¾ç¿¡ ´ëÇÑ ´õ ³ªÀº °ü¸® ¼Ö·ç¼ÇÀ» Á¦°øÇÔÀ¸·Î½á Àüü ½ÃÀåÀÇ ¼ºÀå°ú ȯÀÚ Ä¡·á °³¼±À¸·Î À̾îÁú °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¾à¹° À¯Çüº°·Î º¸¸é Ä­µð´Ù ¿ÜÀ½Áú¿°(VVC) Ä¡·á ½ÃÀåÀÇ ¸ÅÃâÀº Ŭ·ÎÆ®¸®¸¶Á¹ ºÎ¹®ÀÌ 2024-2032³â µÎµå·¯Áø CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Ŭ·ÎÆ®¸®¸¶Á¹Àº Å©¸², Á¾à, °æ±¸¿ë Á¤Á¦ µî ´Ù¾çÇÑ ÇüÅ·ΠÁ¦°øµÇ¸ç, VVC Áõ»óÀ» È¿°úÀûÀ¸·Î ¿ÏÈ­Çϰí ÀÌ ÈçÇÑ Áø±Õ °¨¿°ÁõÀ» °ü¸®Çϱâ À§ÇÑ ±âÃʰ¡ µÇ°í ÀÖ½À´Ï´Ù. ¿À·£ ±â°£ Áß ÀÔÁõµÈ È¿°ú¿Í ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏ·Î ÀÎÇØ ÀÇ·áÁø°ú ȯÀÚµé »çÀÌ¿¡¼­ ²ÙÁØÇÑ Àα⸦ ´©¸®°í ÀÖ½À´Ï´Ù. Ŭ·ÎÆ®¸®¸¶Á¹ÀÇ ¾ÈÁ¤ÀûÀÎ °¡¿ë¼º°ú ºñ¿ë È¿À²¼ºÀº ½ÃÀå¿¡¼­ ¼ö¿ä¸¦ ´õ¿í Áö¿øÇϰí ÀÖÀ¸¸ç, VVC°¡ ¿©ÀüÈ÷ À¯ÇàÇϰí ÀÖ´Â °¡¿îµ¥ Ŭ·ÎÆ®¸®¸¶Á¹ÀÇ Ä¡·á ¿ªÇÒÀº VVC Ä¡·á¿¡¼­ Áö¼ÓÀûÀÎ Á¸Àç¿Í Á߿伺À» º¸ÀåÇϰí ÀÖ½À´Ï´Ù.

Áúº´ À¯Çüº°·Î´Â 2024-2032³â ÇÕº´Áõ VVC ºÎ¹®ÀÌ µÎµå·¯Áø ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÇÕº´Áõ VVC´Â Àç¹ß¼º ¶Ç´Â ÁßÁõ °¨¿°ÀÌ Æ¯Â¡À̸ç, ÇÕº´ÁõÀÌ ¾ø´Â °æ¿ì¿Í ºñ±³ÇßÀ» ¶§ ´õ ³ôÀº ¼öÁØÀÇ Ä¡·á Á¢±ÙÀÌ ÇÊ¿äÇÑ °æ¿ì°¡ ¸¹½À´Ï´Ù. ÀÌ¿¡ µû¶ó »õ·Î¿î °æ±¸ ¹× ±¹¼Ò Ä¡·áÁ¦¸¦ Æ÷ÇÔÇÑ Çõ½ÅÀûÀÎ Ç×Áø±ÕÁ¦ °³¹ß ¹× ½ÃÀå °³Ã´¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. È¿°úÀûÀÎ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä´Â Àç¹ß·ü °¨¼Ò¿Í ȯÀÚ ¿¹ÈÄ °³¼±ÀÇ Çʿ伺¿¡ ÀÇÇØ »ý°Ü³ª°í ÀÖ½À´Ï´Ù. ÀÇ·áÁøÀÌ º¹ÀâÇÑ ¿ÜÀ½ºÎ Ä­µð´ÙÁõÀ» º¸´Ù È¿°úÀûÀ¸·Î °ü¸®ÇÒ ¼ö ÀÖ´Â ¹æ¹ýÀ» ¸ð»öÇÏ´Â °¡¿îµ¥, ÷´Ü Ä¡·á ¼Ö·ç¼ÇÀÇ µµÀÔÀ¸·Î ½ÃÀåÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù.

À¯·´ÀÇ Ä­µð´Ù ¿ÜÀ½Áú¿°(VVC) Ä¡·á ½ÃÀåÀº 2024-2032³â »ó´çÇÑ CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿©¼º °Ç°­¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó À¯·´ ÀÇ·á ½Ã½ºÅÛÀº ¸¹Àº ¿©¼º¿¡°Ô ³Î¸® ÆÛÁ® ÀÖ´Â Áø±Õ °¨¿°ÁõÀÎ VVC¸¦ È¿°úÀûÀ¸·Î °ü¸®ÇÒ ¼ö ÀÖ´Â ¿É¼ÇÀ» ¿ì¼±½ÃÇϰí ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀ» ÁÖµµÇÏ´Â °ÍÀº ¹Ù¸£´Â Ç×Áø±ÕÁ¦ ¹× °æ±¸¿ë Ç×Áø±ÕÁ¦¸¦ Æ÷ÇÔÇÑ Ã³¹æÀü ¾øÀÌ ±¸ÀÔÇÒ ¼ö ÀÖ´Â Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿äÀÔ´Ï´Ù. À¯·´ÀÇ ±ÔÁ¦¿Í Á¤Ã¥Àº Çõ½ÅÀûÀÎ Ä¡·á¹ýÀÇ »ç¿ëÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ±× °á°ú, Á¦¾à»çµéÀº Áö¿ª ÀüüÀÇ È¿°úÀûÀÎ VVC Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃæÁ·½Ã۱â À§ÇØ ½ÅÁ¦Ç° °³¹ß ¹× Ãâ½Ã¿¡ Àû±ØÀûÀ¸·Î ³ª¼­°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå °³¿ä

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

  • ¿¡ÄڽýºÅÛ ºÐ¼®
  • ¾÷°è¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
    • ÃËÁø¿äÀÎ
      • Ä­µð´Ù Áú¿°ÀÇ À¯º´·ü Áõ°¡
      • ½ÃÆÇ¾àÀÇ °¡¿ë¼º
      • ¿©¼º °Ç°­¿¡ ´ëÇÑ °ü½ÉÀÇ Áõ°¡
    • ¾÷°èÀÇ ÀáÀçÀû ¸®½ºÅ© & °úÁ¦
      • Ç×Áø±ÕÁ¦¿¡ ¼ö¹ÝÇÏ´Â ºÎÀÛ¿ë
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • ±ÔÁ¦ »óȲ
    • ¹Ì±¹
    • À¯·´
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®
  • »óȯ »óȲ
  • ÇâÈÄ ½ÃÀå µ¿Çâ
  • PorterÀÇ »ê¾÷ ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼­·Ð
  • ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®
  • ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ °æÀï ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« ´ë½Ãº¸µå

Á¦5Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : ¾àÁ¦ Ŭ·¡½ºº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • Fluconazole
  • Clotrimazole
  • Miconazole
  • Nystatin
  • Ketoconazole
  • Terbinafine
  • Terconazole
  • ±âŸ ¾àÁ¦ Ŭ·¡½ºº°

Á¦6Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : Áúȯ À¯Çüº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ºñÇÕº´Çü VVC
  • ÇÕº´Áõ¼º VVC

Á¦7Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : Åõ¿© °æ·Îº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • °æ±¸Á¦
  • ±¹¼Ò
  • Á¤¸Æ³» Åõ¿©

Á¦8Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : À¯Çüº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • 󹿾à
  • OTC ÀǾàǰ

Á¦9Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : À¯Åë ä³Îº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹

Á¦10Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : Áö¿ªº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ³×´ú¶õµå
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦11Àå ±â¾÷ °³¿ä

  • Accord Healthcare Ltd.
  • Amneal Pharmaceuticals LLC
  • Astellas Pharma Inc.
  • Basilea Pharmaceutica Ltd.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Grupo Ferrer Internacional S.A.
  • Johnson & Johnson
  • Mycovia Pharmaceuticals, Inc.
  • Mylan N.V.
  • Pfizer, Inc.
  • Scynexis, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Cadila
KSA 24.08.28

Global Vulvovaginal Candidiasis (VVC) Treatment Market will witness 4.5% CAGR between 2024 and 2032 due to the surge in product launches from leading pharmaceutical companies. VVC, a common fungal infection caused by Candida species, affects millions of women globally, prompting a significant need for effective treatments. In response, major players in the healthcare sector are introducing a variety of innovative antifungal therapies and over-the-counter treatments, including topical creams, oral medications, and intravaginal suppositories.

For instance, in February 2024, Mycovia Pharmaceuticals, Inc., an emerging biopharmaceutical company, announced that Jiangsu Hengrui Pharmaceuticals Co., Ltd officially launched VIVJOA(R) (oteseconazole) in China. This innovative oral azole antifungal is now available for treating severe vulvovaginal candidiasis (VVC).

These new product launches address the growing demand for more effective, accessible, and patient-friendly treatment options. Companies are investing in research and development to enhance efficacy, reduce recurrence rates, and minimize side effects. The introduction of novel formulations and delivery methods reflects a commitment to meeting diverse patient needs and improving treatment outcomes. As the market expands with these advancements, it is poised to provide better management solutions for VVC, driving overall market growth and enhancing patient care.

The overall Vulvovaginal Candidiasis (VVC) Treatment Industry is classified based on the drug class, disease type, route of administration, type, distribution channel, and region.

Based on drug class, the vulvovaginal candidiasis (VVC) treatment market revenue from the clotrimazole segment will register a commendable CAGR from 2024 to 2032. Clotrimazole, available in various forms such as creams, suppositories, and oral tablets, offers effective relief from VVC symptoms and is a cornerstone in managing this common fungal infection. Its long-standing efficacy and safety profile contribute to its continued popularity among healthcare providers and patients. The consistent availability of clotrimazole and its cost-effectiveness further support its demand in the market. As VVC remains prevalent, clotrimazole's role in treatment ensures its sustained presence and significance in the VVC treatment landscape.

In terms of disease type, the complicated VVC segment will witness appreciable growth from 2024 to 2032. Complicated VVC, characterized by recurrent or severe infections, often requires more advanced treatment approaches compared to uncomplicated cases. This has led to an increased focus on developing and marketing innovative antifungal treatments, including newer oral and topical therapies. The demand for effective solutions is driven by the need for reduced recurrence rates and improved patient outcomes. As healthcare providers seek more effective management options for complicated VVC, the market is expanding with the introduction of advanced therapeutic solutions.

Europe vulvovaginal candidiasis (VVC) treatment market will exhibit a notable CAGR from 2024 to 2032. With a growing emphasis on women's health, European healthcare systems are prioritizing effective management options for VVC, which is a prevalent fungal infection affecting many women. The market is driven by the need for both over-the-counter and prescription treatments, including topical and oral antifungals. European regulations and healthcare policies further support the availability of innovative therapies. As a result, pharmaceutical companies are actively developing and launching new products to meet the demand for effective VVC treatments across the region.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of vulvovaginal candidiasis
      • 3.2.1.2 Availability of over-the-counter medications
      • 3.2.1.3 Increasing focus on women's health
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Adverse effects associated with antifungal medications
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
    • 3.4.1 U.S.
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
  • 3.5 Pipeline analysis
  • 3.6 Reimbursement landscape
  • 3.7 Future market trends
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Fluconazole
  • 5.3 Clotrimazole
  • 5.4 Miconazole
  • 5.5 Nystatin
  • 5.6 Ketoconazole
  • 5.7 Terbinafine
  • 5.8 Terconazole
  • 5.9 Other drug classes

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Uncomplicated VVC
  • 6.3 Complicated VVC

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Oral
  • 7.3 Topical
  • 7.4 Intravenous

Chapter 8 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Prescription drugs
  • 8.3 OTC drugs

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 Hospital pharmacies
  • 9.3 Retail pharmacies
  • 9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 10.1 Key trends
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 France
    • 10.3.4 Spain
    • 10.3.5 Italy
    • 10.3.6 Netherlands
    • 10.3.7 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 China
    • 10.4.2 Japan
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 South Korea
    • 10.4.6 Rest of Asia Pacific
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Rest of Latin America
  • 10.6 Middle East and Africa
    • 10.6.1 South Africa
    • 10.6.2 Saudi Arabia
    • 10.6.3 UAE
    • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

  • 11.1 Accord Healthcare Ltd.
  • 11.2 Amneal Pharmaceuticals LLC
  • 11.3 Astellas Pharma Inc.
  • 11.4 Basilea Pharmaceutica Ltd.
  • 11.5 Bayer AG
  • 11.6 Bristol-Myers Squibb Company
  • 11.7 Grupo Ferrer Internacional S.A.
  • 11.8 Johnson & Johnson
  • 11.9 Mycovia Pharmaceuticals, Inc.
  • 11.10 Mylan N.V.
  • 11.11 Pfizer, Inc.
  • 11.12 Scynexis, Inc.
  • 11.13 Teva Pharmaceutical Industries Ltd.
  • 11.14 Zydus Cadila
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦